RCP
NBIX icon

Rothschild Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History

Rothschild Capital Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-39,700
Closed -$2.01M – 66
2016
Q3 		$2.01M Buy
+39,700
New +$1.98M 0.72% 45

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Rothschild Capital Partners's NBIX Position: Q4 2016 in Review

Rothschild Capital Partners sold out of Neurocrine Biosciences (NBIX) in Q4 2016, closing a stake of 39,700 shares — an estimated $2.01M sold.

Rothschild Capital Partners first reported a position in NBIX in Q3 2016 and held it in 1 quarter. The position peaked at $2.01M in Q3 2016. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

  • Rothschild Capital Partners reported no remaining Neurocrine Biosciences position as of Q4 2016 after selling out during the quarter.
  • Rothschild Capital Partners sold 39,700 Neurocrine Biosciences shares in Q4 2016, an estimated $2.01M.
  • Rothschild Capital Partners first reported a position in Neurocrine Biosciences in Q3 2016 and held it in 1 quarter.
  • Rothschild Capital Partners's Neurocrine Biosciences position peaked at $2.01M in Q3 2016.
  • 225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on Rothschild Capital Partners's 13F filing for Q4 2016, filed 30 Jan 2017.